Tetrahydroxystilbene glucoside ameliorates diabetic nephropathy in rats: Involvement of SIRT1 and TGF-β1 pathway

European Journal of Pharmacology

Volumn 649, Issue 1-3, 2010, Pages 382-389

  Li, Cairong ^a   Cai, Fei ^a   Yang, Yinqiao ^a   Zhao, Xinyuan ^a   Wang, Chun ^b   Li, Juan ^a   Jia, Yanlong ^a   Tang, Jing ^a   liu, Qing ^a  

^a HUBEI UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Xianning Central Hospital   (China)

Author keywords

2,3,5,4' tetrahydroxystilbene 2 O d glucoside (TSG); Diabetic nephropathy; Mesangial cell; SIRT1; TGF 1

Indexed keywords

2,3,5,4' TETRAHYDROXYSTILBENE 2 O BETA DEXTRO GLUCOSIDE; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CHOLESTEROL; CREATININE; CYCLOOXYGENASE 2 INHIBITOR; GLUCOSE; GLUTATHIONE PEROXIDASE; MALONALDEHYDE; NITROGEN; PLANT EXTRACT; POLYGONUM MULTIFLORUM EXTRACT; SIRTUIN 1; SUPEROXIDE DISMUTASE; TRANSFORMING GROWTH FACTOR BETA1; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UREA;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD GLUCOSE MONITORING; BLOOD SAMPLING; BODY WEIGHT; CELL VIABILITY; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; ENZYME ACTIVATION; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; KIDNEY FUNCTION; KIDNEY MASS; LOW DRUG DOSE; MALE; MESANGIUM CELL; NONHUMAN; OXIDATIVE STRESS; POLYGONUM; POLYGONUM MULTIFLORUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SPRAGUE DAWLEY RAT; UREA NITROGEN BLOOD LEVEL;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; BIOLOGICAL MARKERS; CELL LINE; CYCLOOXYGENASE 2; DIABETIC NEPHROPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOSIDES; HISTONE DEACETYLASE INHIBITORS; HYPERGLYCEMIA; KIDNEY CORTEX; MALE; MESANGIAL CELLS; OXIDATIVE STRESS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; SIRTUIN 1; STILBENES; TRANSFORMING GROWTH FACTOR BETA1;

EID: 78049290400     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.09.004     Document Type: Article

References (31)

1. Akai Y., Sato H., Ozaki H., Iwano M., Dohi Y., Kanauchi M. Association of transforming growth factor-beta1 T29C polymorphism with the progression of diabetic nephropathy. Am. J. Kidney Dis. 2001, 38:S182-S185.
2. Brunet A., Sweeney L.B., Sturgill J.F., Chua K.F., Greer P.L., Lin Y., Tran H., Ross S.E., Mostoslavsky R., Cohen H.Y., Hu L.S., Cheng H.L., Jedrychowski M.P., Gygi S.P., Sinclair D.A., Alt F.W., Greenberg M.E. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004, 303:2011-2015.
3. Cai F., Wang F., Lin F.K., Liu C., Ma L.Q., Liu J., Wu W.N., Wang W., Wang J.H., Chen J.G. Redox modulation of long-term potentiation in the hippocampus via regulation of the glycogen synthase kinase-3beta pathway. Free Radic. Biol. Med. 2008, 45:964-970.
4. Cheng H.F., Wang C.J., Moeckel G.W., Zhang M.Z., McKanna J.A., Harris R.C. Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension. Kidney Int. 2002, 62:929-939.
5. Ha H., Lee H.B. Reactive oxygen species as glucose signaling molecules in mesangial cells cultured under high glucose. Kidney Int. Suppl. 2000, 77:S19-S25.
6. Han D.C., Isono M., Hoffman B.B., Ziyadeh F.N. High glucose stimulates proliferation and collagen type I synthesis in renal cortical fibroblasts: mediation by autocrine activation of TGF-beta. J. Am. Soc. Nephrol. 1999, 10:1891-1899.
7. Imai S., Armstrong C.M., Kaeberlein M., Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 2000, 403:795-800.
8. Kanwar Y.S., Wada J., Sun L., Xie P., Wallner E.I., Chen S., Chugh S., Danesh F.R. Diabetic nephropathy: mechanisms of renal disease progression. Exp. Biol. Med. (Maywood) 2008, 233:4-11.
9. Kiritoshi S., Nishikawa T., Sonoda K., Kukidome D., Senokuchi T., Matsuo T., Matsumura T., Tokunaga H., Brownlee M., Araki E. Reactive oxygen species from mitochondria induce cyclooxygenase-2 gene expression in human mesangial cells: potential role in diabetic nephropathy. Diabetes 2003, 52:2570-2577.
10. Komers R., Lindsley J.N., Oyama T.T., Anderson S. Cyclo-oxygenase-2 inhibition attenuates the progression of nephropathy in uninephrectomized diabetic rats. Clin. Exp. Pharmacol. Physiol. 2007, 34:36-41.
11. Kume S., Haneda M., Kanasaki K., Sugimoto T., Araki S., Isono M., Isshiki K., Uzu T., Kashiwagi A., Koya D. Silent information regulator 2 (SIRT1) attenuates oxidative stress-induced mesangial cell apoptosis via p53 deacetylation. Free Radic. Biol. Med. 2006, 40:2175-2182.
12. Kume S., Haneda M., Kanasaki K., Sugimoto T., Araki S., Isshiki K., Isono M., Uzu T., Guarente L., Kashiwagi A., Koya D. SIRT1 inhibits transforming growth factor beta-induced apoptosis in glomerular mesangial cells via Smad7 deacetylation. J. Biol. Chem. 2007, 282:151-158.
13. Lee H.B., Yu M.R., Yang Y., Jiang Z., Ha H. Reactive oxygen species-regulated signaling pathways in diabetic nephropathy. J. Am. Soc. Nephrol. 2003, 14:S241-S245.
14. Petersen M., Thorikay M., Deckers M., van Dinther M., Grygielko E.T., Gellibert F., de Gouville A.C., Huet S., ten Dijke P., Laping N.J. Oral administration of GW788388, an inhibitor of TGF-beta type I and II receptor kinases, decreases renal fibrosis. Kidney Int. 2008, 73:705-715.
15. Rosen P., Nawroth P.P., King G., Moller W., Tritschler H.J., Packer L. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab. Res. Rev. 2001, 17:189-212.
16. Rossing P. Diabetic nephropathy: worldwide epidemic and effects of current treatment on natural history. Curr. Diab. Rep. 2006, 6:479-483.
17. Schrijvers B.F., De Vriese A.S., Flyvbjerg A. From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr. Rev. 2004, 25:971-1010.
18. Sharma K., McGowan T.A. TGF-beta in diabetic kidney disease: role of novel signaling pathways. Cytokine Growth Factor Rev. 2000, 11:115-123.
19. Sharma K., Ziyadeh F.N. Renal hypertrophy is associated with upregulation of TGF-beta 1 gene expression in diabetic BB rat and NOD mouse. Am. J. Physiol. 1994, 267. F1094-1001.
20. Sharma K., Ziyadeh F.N. Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator. Diabetes 1995, 44:1139-1146.
21. Sharma K., Jin Y., Guo J., Ziyadeh F.N. Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 1996, 45:522-530.
22. Sharma S., Anjaneyulu M., Kulkarni S.K., Chopra K. Resveratrol, a polyphenolic phytoalexin, attenuates diabetic nephropathy in rats. Pharmacology 2006, 76:69-75.
23. Shore D. The Sir2 protein family: a novel deacetylase for gene silencing and more. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:14030-14032.
24. Tikoo K., Singh K., Kabra D., Sharma V., Gaikwad A. Change in histone H3 phosphorylation, MAP kinase p38, SIR 2 and p53 expression by resveratrol in preventing streptozotocin induced type I diabetic nephropathy. Free Radic. Res. 2008, 42:397-404.
25. Wahab N.A., Harper K., Mason R.M. Expression of extracellular matrix molecules in human mesangial cells in response to prolonged hyperglycaemia. Biochem. J. 1996, 316(Pt 3):985-992.
26. Wang T., Gu J., Wu P.F., Wang F., Xiong Z., Yang Y.J., Wu W.N., Dong L.D., Chen J.G. Protection by tetrahydroxystilbene glucoside against cerebral ischemia: involvement of JNK, SIRT1, and NF-kappaB pathways and inhibition of intracellular ROS/RNS generation. Free Radic. Biol. Med. 2009, 47:229-240.
27. Wolf G., Sharma K., Chen Y., Ericksen M., Ziyadeh F.N. High glucose-induced proliferation in mesangial cells is reversed by autocrine TGF-beta. Kidney Int. 1992, 42:647-656.
28. Yamamoto T., Nakamura T., Noble N.A., Ruoslahti E., Border W.A. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:1814-1818.
29. Yamamoto T., Noble N.A., Miller D.E., Border W.A. Sustained expression of TGF-beta 1 underlies development of progressive kidney fibrosis. Kidney Int. 1994, 45:916-927.
30. Zhang Y.Z., Shen J.F., Xu J.Y., Xiao J.H., Wang J.L. Inhibitory effects of 2, 3, 5, 4'-tetrahydroxystilbene-2-O-beta-d-glucoside on experimental inflammation and cyclooxygenase 2 activity. J. Asian Nat. Prod. Res. 2007, 9:355-363.
31. Ziyadeh F.N., Hoffman B.B., Han D.C., Iglesias-De La Cruz M.C., Hong S.W., Isono M., Chen S., McGowan T.A., Sharma K. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:8015-8020.